Tigenix « Terug naar discussie overzicht

Tigenix november 2017

436 Posts, Pagina: « 1 2 3 4 5 6 ... 14 15 16 17 18 19 20 21 22 » | Laatste
StofkeVN
0
quote:

four60 schreef op 26 november 2017 17:43:

gemiddelde? Begrijp ik niet.
Gemiddelde aankoopprijs veronderstel ik ;-)
Aandeel123
0
bodem
0
Proficiat u hebt marge, die nasdaq heeft me genekt omdat ik heb gekocht na de takeda deal.
TheBateman
0
The Group directors concluded that the significant influence over its TiGenix investment has
ceased. The facts that lead to that conclusion are the resignation of its preferred rights to
distribute the main drug under investigation by TiGenix and the fact that Grifols Group has no
longer appointed board members and do not expect to have any. Additionally it has been
considered the fact that the time needed for exercising its right of appointment of one board
director is too long as to allow Grifols to participate in the board decisions in due time.
As a consequence the investment in TiGenix has been reclassified to Available for Sale Financial
Assets. The effect of this reclassification resulted in a revaluation of the investment at fair value
and the related gain amounting to Euros 24 million has been accounted for in Share of
[verwijderd]
0
quote:

four60 schreef op 26 november 2017 15:26:

Ik heb een flinke pluk Tigenix en ga voor de langere termijn belegging tenzij ze worden overgenomen.
Eens. Zo zie ik het ook.
Er zijn gewoon zeer veel en zwaarwegende tekenen en feiten dat er een mooie toekomst is op de korte en op de wat langere termijn.

Bio-marker
0
quote:

TheBateman schreef op 27 november 2017 00:23:

The Group directors concluded that the significant influence over its TiGenix investment has
ceased. The facts that lead to that conclusion are the resignation of its preferred rights to
distribute the main drug under investigation by TiGenix and the fact that Grifols Group has no
longer appointed board members and do not expect to have any. Additionally it has been
considered the fact that the time needed for exercising its right of appointment of one board
director is too long as to allow Grifols to participate in the board decisions in due time.
As a consequence the investment in TiGenix has been reclassified to Available for Sale Financial
Assets. The effect of this reclassification resulted in a revaluation of the investment at fair value
and the related gain amounting to Euros 24 million has been accounted for in Share of
Dank hiervoor. Wat is bron en datum?
Semper Nescio
0
quote:

TheBateman schreef op 27 november 2017 00:23:

The Group directors concluded that the significant influence over its TiGenix investment has
ceased. The facts that lead to that conclusion are the resignation of its preferred rights to
distribute the main drug under investigation by TiGenix and the fact that Grifols Group has no
longer appointed board members and do not expect to have any. Additionally it has been
considered the fact that the time needed for exercising its right of appointment of one board
director is too long as to allow Grifols to participate in the board decisions in due time.
As a consequence the investment in TiGenix has been reclassified to Available for Sale Financial
Assets. The effect of this reclassification resulted in a revaluation of the investment at fair value
and the related gain amounting to Euros 24 million has been accounted for in Share of
Kun je even een link naar het volledige artikel bezorgen? Zou graag eens het volledige artikel lezen.
whoiam
0
ik zit nog niet in tigenix, maar lees nu de laatste dagen dit forum, lijkt me een goed inkoopmoment met veel potentieel? ben aan het twijfelen voor deel kiadis te verkopen en deel tigenix te kopen, wat denken jullie?
Rider
0
quote:

whoiam schreef op 27 november 2017 11:52:

ik zit nog niet in tigenix, maar lees nu de laatste dagen dit forum, lijkt me een goed inkoopmoment met veel potentieel? ben aan het twijfelen voor deel kiadis te verkopen en deel tigenix te kopen, wat denken jullie?
Ik zit in beide. Heb wel dubbel zoveel Kiadis als Tigenix.
posilies
0
quote:

TheBateman schreef op 27 november 2017 00:23:

The Group directors concluded that the significant influence over its TiGenix investment has
ceased. The facts that lead to that conclusion are the resignation of its preferred rights to
distribute the main drug under investigation by TiGenix and the fact that Grifols Group has no
longer appointed board members and do not expect to have any. Additionally it has been
considered the fact that the time needed for exercising its right of appointment of one board
director is too long as to allow Grifols to participate in the board decisions in due time.
As a consequence the investment in TiGenix has been reclassified to Available for Sale Financial
Assets. The effect of this reclassification resulted in a revaluation of the investment at fair value
and the related gain amounting to Euros 24 million has been accounted for in Share of
Niet zo positief
four70
0
Ik vraag mij af of JPMorgan die miljoenenorder Tigenix via Brussel of de NASDAQ heeft aangeschaft, kan dit nergens vinden. Wie weet dat?
Semper Nescio
0
quote:

posilies schreef op 27 november 2017 12:08:

[...]
Niet zo positief
Een rapport van een jaar geleden? Da's dan echt wel heel oud nieuws hé?
Rider
0
quote:

Leek55 schreef op 27 november 2017 13:23:

Geert Schaaij begint een advies tot kopen te geven.

bron?
Leek55
0
quote:

four60 schreef op 27 november 2017 12:18:

Ik vraag mij af of JPMorgan die miljoenenorder Tigenix via Brussel of de NASDAQ heeft aangeschaft, kan dit nergens vinden. Wie weet dat?
tigenix.com/news-media/
Leek55
0
quote:

rider13 schreef op 27 november 2017 13:31:

[...]

bron?
Ik krijg er net een mail over.
436 Posts, Pagina: « 1 2 3 4 5 6 ... 14 15 16 17 18 19 20 21 22 » | Laatste
Aantal posts per pagina:  20 50 100 | Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met uw e-mailadres en wachtwoord.

Direct naar Forum

Markt vandaag

AEX 882,63 +12,36 +1,42% 26 apr
AMX 914,42 -2,12 -0,23% 26 apr
ASCX 1.198,74 +7,95 +0,67% 26 apr
BEL 20 3.874,87 +16,93 +0,44% 26 apr
Germany40^ 18.177,90 +260,62 +1,45% 26 apr
US30^ 38.211,61 0,00 0,00% 26 apr
US500^ 5.095,29 0,00 0,00% 26 apr
Nasd100^ 17.698,09 0,00 0,00% 26 apr
Japan225^ 38.345,55 0,00 0,00% 26 apr
WTI 83,64 0,00 0,00% 26 apr
Brent 87,99 0,00 0,00% 26 apr
EUR/USD 1,0694 -0,0036 -0,33% 26 apr
BTC/USD 63.101,97 -877,90 -1,37% 02:59
Gold spot 2.337,95 0,00 0,00% 26 apr
#/^ Index indications calculated real time, zie disclaimer
HOGE RENDEMENTEN OP DE IEX-MODELPORTEFEUILLES > WORD NU ABONNEE EN PROFITEER VAN MAAR LIEFST 67% KORTING!

Stijgers & Dalers

Stijgers Laatst +/- % tijd
ASMI 623,800 +42,200 +7,26% 26 apr
ASML 858,800 +25,100 +3,01% 26 apr
PROSUS 31,625 +0,815 +2,65% 26 apr
Dalers Laatst +/- % tijd
IMCD 141,700 -7,300 -4,90% 26 apr
ABN AMRO BANK N.V. 15,210 -0,665 -4,19% 26 apr
BESI 130,400 -5,600 -4,12% 26 apr

EU stocks, real time, by Cboe Europe Ltd.; Other, Euronext & US stocks by NYSE & Cboe BZX Exchange, 15 min. delayed
#/^ Index indications calculated real time, zie disclaimer, streaming powered by: Infront